title: Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.
abstract: OBJECTIVE
  To examine the frequency of PSA testing in men aged ≥75 years before and after the 2008 US Preventive Services Task Force (USPSTF) recommendation to stop prostate-specific antigen (PSA) screening at age 75.
  
  
  METHODS
  Data were obtained from the Behavioral Risk Factor Surveillance System (BRFSS) surveys completed in 2006, 2008 and 2010. Men aged ≥ 76 years at the time of survey and without a prostate cancer diagnosis were included in the study. The percentage of men who had a PSA test in the year before the survey was computed separately for survey years 2006, 2008 and 2010.
  
  
  RESULTS
  The estimated percentages of men with a PSA test in the year before the survey were 60% (95% CI: 58-62%), based on 9033 respondents interviewed in 2006, 63% (95% CI: 62-65%), based on 12,063 respondents interviewed in 2008, and 60% (95% CI: 59-61%), based on 14,782 respondents interviewed in 2010.
  
  
  CONCLUSIONS
  No substantial reduction in the frequency of PSA testing was observed in the BRFSS 2010 survey data compared with the earlier years, suggesting that the USPSTF 2008 recommendation had no major impact on the frequency of PSA testing in older men in the USA.
authors.affiliation: Department of Urology, University of Rochester Medical Center, NY, USA.
authors.forename: Emil
authors.initials: E
authors.lastname: Scosyrev
authors.forename: Guan
authors.initials: G
authors.lastname: Wu
authors.forename: Dragan
authors.initials: D
authors.lastname: Golijanin
authors.forename: Edward
authors.initials: E
authors.lastname: Messing
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D040343:Behavioral Risk Factor Surveillance System; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D014481:United States
chemical_list: D017430:Prostate-Specific Antigen